Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00292929 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety of Intravenous Artesunate
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00292929: Completed Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
NCT00292929 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00292929, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the safety, tolerability and pharmacokinetics of a single dose of the antimalarial drug artesunate.
Interventions
- DRUG Intravenous artesunate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
What the finished NCT00292929 record still lists
NCT00292929 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 1 intervention - of which Intravenous artesunate is the first listed.
NCT00292929 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00292929 about?
NCT00292929 is a clinical study titled "Study of the Safety of Intravenous Artesunate". The purpose of this study is to establish the safety, tolerability and pharmacokinetics of a single dose of the antimalarial drug artesunate.
What is the current status of trial NCT00292929?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00292929?
The interventions under investigation include: Intravenous artesunate (DRUG).
Who is sponsoring clinical trial NCT00292929?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00292929's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models